TGA slaps new restrictions on osteoporosis drug

Strontium ranelate should be restricted to a last-line therapy for osteoporosis and strictly avoided in patients with heart disease, the TGA has formally advised pharmacists.

The changes to the drug's product information follow a recent European investigation, which imposed extra restrictions on the drug but stopped short of an outright ban.